2021
Miglustat Therapy for SCARB2-Associated Action Myoclonus–Renal Failure Syndrome
Quraishi IH, Szekely AM, Shirali AC, Mistry PK, Hirsch LJ. Miglustat Therapy for SCARB2-Associated Action Myoclonus–Renal Failure Syndrome. Neurology Genetics 2021, 7: e614. PMID: 34337151, PMCID: PMC8320328, DOI: 10.1212/nxg.0000000000000614.Peer-Reviewed Original ResearchAction myoclonus-renal failure syndromeNeurologic symptomsAction myoclonusFailure syndromeProgressive myoclonic epilepsySubstrate reduction therapyWhole-exome sequencingMiglustat therapyAvailable medicationsEarly mortalityReduction therapyMyoclonic epilepsySteady worseningGaucher diseaseMyoclonusGlycosphingolipid metabolismExome sequencingGene mutationsGlucosylceramide accumulationPatientsSeizuresMiglustatSyndromeTherapySymptoms
2019
Reversal of life-threatening hepatopulmonary syndrome in Gaucher disease by imiglucerase enzyme replacement therapy
Beshlawy AE, Murugesan V, Mistry PK, Eid K. Reversal of life-threatening hepatopulmonary syndrome in Gaucher disease by imiglucerase enzyme replacement therapy. Molecular Genetics And Metabolism Reports 2019, 20: 100490. PMID: 31309038, PMCID: PMC6606832, DOI: 10.1016/j.ymgmr.2019.100490.Peer-Reviewed Original ResearchImiglucerase enzyme replacement therapyEnzyme replacement therapyHepatopulmonary syndromeReplacement therapyGaucher diseaseLiver diseaseRecombinant enzyme replacement therapyAdvanced liver diseaseLife-threatening complicationsAdvanced fibrosisFibrotic featuresMassive hepatomegalySplenectomized patientsClinical manifestationsEnzyme therapySyndromeTherapyDisease pathologyDiseaseComplicationsMacrophagesCirrhosisHepatomegalyPatientsFibrosis